DLL3 and large cell neuroendocrine carcinoma: Despite negative outcomes with rovalpituzumab (a specific anti-DLL3 antibody drug conjugate) in later stage SCLC, this molecular abnormality may offer a potential target for further drug development in LCNEC [44].